This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
by Zacks Equity Research
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
by Zacks Equity Research
Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.
Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy
by Zacks Equity Research
Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.
Humacyte (HUMA) Completes Enrollment in HAV Technology Study
by Zacks Equity Research
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
by Zacks Equity Research
Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.
Apellis (APLS) Stock Up 50% in Three Months: Here's Why?
by Zacks Equity Research
Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.
Here's Why Allogene Therapeutics (ALLO) is Poised for a Turnaround After Losing -17.44% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Allogene Therapeutics (ALLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
by Zacks Equity Research
Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.
Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod
by Zacks Equity Research
Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.
Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee
by Zacks Equity Research
Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.
Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
by Zacks Equity Research
Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up
by Zacks Equity Research
Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
by Zacks Equity Research
Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA
Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept
by Zacks Equity Research
Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.
Allogene Therapeutics (ALLO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Allogene Therapeutics (ALLO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus
by Zacks Equity Research
Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.
Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.
After Plunging -23.01% in 4 Weeks, Here's Why the Trend Might Reverse for Allogene Therapeutics (ALLO)
by Zacks Equity Research
Allogene Therapeutics (ALLO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
by Zacks Equity Research
Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.
Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.